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BACKGROUND: The association of allergic diseases,
drug adverse reactions and elevated total immuno-
globulin E (IgE) concentration in systemic lupus
erythematosus patients remains controversial. The
aim of the study was to investigate the prevalence of
those features in active and inactive systemic lupus
erythematosus patients, and in the control group as
well.
Methods: Total IgE concentration was evaluated by
enzyme-linked immunosorbent assay
Results and conclusions: The results of our study
revealed that concomitant allergic diseases were not
more frequent in systemic lupus erythematosus
patients than in the general population. Total IgE
concentration was significantly higher during the
active stage of the disease. Drug reactions were very
frequent but not connected with IgE elevation. Our
results indicate that IgE may play a role in lupus
pathogenesis, especially in the active phase of the
disease.
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Introduction
Systemic lupus erythematosus (SLE) remains elusive
in the description of its underlying etiologic causes
and pathogenic mechanisms. Although genetic pre-
disposition appears to contribute to the disease based
on twin and genetic studies, additional factors like
viral and bacterial infections, ultraviolet exposure,
diet, toxins (environmental), and hormonal abnorm-
alities must play a role.
1
Allergy and SLE share some pathophysiological
mechanisms. In both disorders, dysregulation of the
immune system, especially B-cell hyperactivity, lead-
ing to production of various types of immunoglobu-
lins, plays an important role.
2
The literature data concerning the relationship
between diseases with allergic background and SLE,
as well as the contribution of immunoglobulin E (IgE)
to lupus pathogenesis, remain controversial. There-
fore the aim of the study was to investigate the
prevalence of asthma, allergic rhinitis, atopic derma-
titis, urticaria and drug reactions as well as total IgE
serum level in various subgroups of SLE patients.
Materials and methods
The study involved patients with SLE who attended,
out-patient and in-patient, Department of Dermatol-
ogy, Medical University of Lodz between 1998 and
2002. The diagnosis of SLE was based on the revised
criteria of the American Rheumatism Association
(now known as the American College of Rheumatol-
ogy).
3
At the time of the study, each patient underwent a
thorough physical examination. The following la-
boratory parameters were analysed: complete blood
cell count, erythrocyte sedimentation rate, urinalysis,
blood urea, creatinine and fibrinogen levels, C
reactive protein, liver function tests (alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
bilirubin), antinuclear antibodies and lupus band test.
Disease activity was scored according to the
method described by Liang et al.
4 The scale of
Systemic Lupus Activity Measure (SLAM) includes 24
clinical symptoms and eight laboratory parameters.
The maximum score in this system is 84 points. In the
present study, a score between 0 and 15 points was
considered as an inactive disease and above 15 points
as an active disease.
Only patients who were not treated with immuno-
suppressive agents, high doses of steroids or anti-
histamines drugs were included in the study. None of
the subjects had symptoms of viral or parasitic
infection during the study based on clinical examina-
tion and the results of laboratory tests already
mentioned.
The patients and controls were interviewed to
determine the presence of atopic dermatitis, allergic
rhinitis, asthma, family history of atopy, urticaria,
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95drug reactions, and contact dermatitis according to
Goldman et al.
5 Moreover, the diagnosis of asthma,
allergic rhinitis and atopic dermatitis was previously
established by a general practitioner or a specialist in
allergy based on appropriate criteria and diagnostic
tests.
Total IgE concentration was evaluated in patient
sera as well as in age-matched and sex-matched
healthy persons by enzyme-linked immunosorbent
assay using the commercially available UniCAP Total
IgE kit (Pharmacia a Upjohn Diagnostic AB, Uppsala,
Sweden) according to the manufacturer’s instruction.
In five patients, the IgE level was controlled twice
during remission and flare of the disease.
In patients with inactive disease and history of skin
rash, which may have suggested allergic contact
dermatitis, patch tests were also performed with the
European Standard (S-100; Chemotechnique Diag-
nostics, Malmo, Sweden) with a 48-h application time
and readings at 48, 72 and 96 h. The patients were
not treated with corticosteroids or immunosuppres-
sive agents either systemically or topically at least 6
weeks before testing.
The study was performed in accordance with the
Helsinki Declaration and approval of the local Ethics
Committee. Informed consent was obtained from all
patients participating in the study.
Statistical analysis
For the statistical analysis of the data, the range of
measured variables is given (minimum/maximum).
The arithmetic mean values (x), median (Me) and
standard deviation (SD) have also been calculated.
The Shapiro/Wilk’s test was used to evaluate the
distribution. The comparison of variable values in
groups was performed depending on the distribution
of features of the Mann/Whitney test, or the test for
two means for independent samples or the Cochran/
Cox test.
Results
The study involved 72 Caucasian patients (67 females
and five males), aged 20/76 years (mean, 37 years).
The mean duration of the disease was 5 years (range,
1 month/20 years). The patients’ characteristics are
presented in Table 1.
Active disease was found in 24 patients, while 48
patients were in an inactive stage of SLE. During the
time of the study six patients were used anti-malarial
drugs and seven non-steroid anti-inflammatory
agents. Patients who were in the active stage of the
disease donated blood before their treatment was
changed to a more aggressive one. Allergic diseases
were present in 14 out of 72 patients. The most
frequent diagnosis was allergic rhinitis (10/72); less
frequent was atopic dermatitis (2/72) and acute
urticaria (2/72). More than one atopic disease was
diagnosed in two patients. Asthma was diagnosed in
none of the patients.
The total IgE concentration in the SLE group
ranged from 2 to 4015 IU/ml (Me/45.5 IU/ml) and
was significantly higher (p/0.028) than in the
comparable 31 healthy controls, in whom those
values ranged from 3 to 151 IU/ml (Me/24 IU/ml)
(Table 2). The total IgE concentration in 14 SLE
patients with coexistent allergic diseases ranged from
80 to 4015 IU/ml (Me/172 IU/ml) and was statisti-
cally higher than those values in 58 patients without
concomitant allergic diseases, which ranged from 2 to
502 IU/ml (Me/35 IU/ml; p/0.009) and the control
group (range, 3/151 IU/ml; Me/24 IU/ml; p/
0.001). In contrast, the values of total IgE in patients
without allergic diseases and controls did not differ
statistically. The highest total IgE concentration
(mean/2111 IU/ml) was noted in group of patients
with SLE and concomitant atopic dermatitis.
A family history of atopy was reported in 20 out of
72 SLE patients (28%). In those subjects, allergic
rhinitis and asthma were particularly frequent. The
total IgE level in patients with atopic diseases in their
families ranged from 3 to 4015 IU/ml (Me/65.5 IU/
ml) and, although it was higher than in patients
without this disorder (2/502 IU/ml, Me/37 IU/ml),
the difference was not statistically significant (p  /
0.05).
The total IgE concentrations were compared in
different stages of the disease activity (Table 3). The
IgE serum level in 24 patients in the active phase of
the disease ranged from 5 to 1166 IU/ml (Me/152.5
IU/ml) and was significantly higher than in 48
patients during remissions, in which the respective
values ranged from 2 to 4015 IU/ml (Me/31.5 IU/
ml; p/0.003), and in controls (range, 3/151 IU/ml;
Table 1. The SLE patients’ characteristics
Parameter Study group
(n/72)
Percentage (%)
Women 67 93
Men 5 7
Age (years) 20/76 (mean, 37) /
Duration of SLE (years) 0.1/20 (mean, 5) /
Active SLE 24 33.3
Inactive SLE 48 66.7
Allergic diseases (all) 14 19.4
Atopic dermatitis 2 2.8
Alergic rhinitis 10 13.8
Urticaria 2 2.8
Asthma 0 0
Family history of allergy 20 27.8
Drug reactions 26 36.1
Patch tests performed 27 38.8
Patch tests positive 7 9.7
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cally significant differences in IgE concentration
between inactive SLE patients and the control group.
In five patients aged 20/50 years, the total IgE
levels were evaluated in the inactive phase and
during lupus flares. The IgE concentration during
remissions ranged between 34 and 150 IU/ml
(mean/98.69 /41.6 IU/ml, Me/100 IU/ml) and
was statistically significantly lower (pB/0.005) than
during active phase of the disease, where the
respective values ranged between 172 and 306 IU/
ml (mean/240.49 /64.3 IU/ml, Me/250 IU/ml).
Drug reactions were noted in 26 out of 72 analysed
SLE patients. Urticaria, oedema, rashes and anaphy-
lactic reactions were most often caused by antibiotics.
These types of reactions were noticed in 15 patients.
Penicillin/cephalosporin (10 cases), gentamycin (two
cases), and tetracyclin (three cases) were the main
cause of drug reactions. Less frequently, non-steroid
anti-inflammatory drugs (four cases), sulphonamides
(three cases) and sulphones (two cases), codeine
(one case) and pentoxifylline (one case) were noted.
Four patients reported that these symptoms were
caused by more than one drug. At the time of the
study, it was not possible to establish the exact
mechanism of each drug adverse reaction.
Exacerbations of the disease (lupus flares) were
confirmed by physicians as related to the drug only in
four of 72 patients. Total IgE concentrations in SLE
patients with drug reactions ranged from 2 to 518 IU/
ml (Me/40.5 IU/ml) and were not statistically
different compared with the respective values in
SLE patients without drug reactions (range, 2/4015
IU/ml; Me/49.1 IU/ml; p /0.05).
Patch tests that were performed in 27/72 (37.5%)
patients aged 21/57 years (mean/38 years) with
history, which may have suggested contact dermati-
tis, revealed allergic reactions to at least one allergen
in seven. There were four reactions to nickel (14.8%),
two reactions to chromate (7.4%), two to fragrance
mix (7.4%), two to wool alcohols (7.4%), two to
mercaptobenzothiazole (7.4%), and a single reaction
to benzocaine, cobalt, phenylenediamine and neo-
mycin. Reactions to six allergens were observed in a
patient with antiphospholipid syndrome and a long
history of leg ulcer.
Discussion
The frequency of allergic diseases and total IgE
concentration in SLE patients were analysed by
several authors but until now some controversies
have remained. Goldman et al.
5 were the first who
documented that in the SLE group allergic rhinitis and
drug allergy had higher incidence, although IgE
levels were not different from those in healthy
population. Sequeira et al.
6 found that 132 patients
with SLE had significantly higher numbers of drug,
skin and insect allergies than 66 individuals with non-
SLE disorders.
There were also some attempts to explain why
patients with lupus have more allergies. Diumenjo et
al.
7 postulated a higher level of hypersensitivity to
exogenous antigens through anaphylactoid products
of complement activation. Gruber et al.
8 found IgM/
anti-IgE (in 27%) and IgG/anti-IgE (in 34%) anti-
bodies in 67 patients with SLE.
The results of our study revealed concomitant
allergic diseases in 19% of patients, which is not
higher than in general population of inhabitants in
our region (22.2%).
9 Our observations are in line with
those obtained by Morton et al.,
10 who revealed no
significant differences in frequency of allergic dis-
orders in 49 SLE cases and 98 controls. Results
presented by Shahar and Lorber
11 exposed signifi-
Table 2. Total IgE concentration in SLE patients with and without allergy and in control group
Total IgE concentration (IU/ml) Statistical signif-
icance
All SLE patients
(n/72) (a)
SLE patients with allergic
diseases (n/14) (b)
SLE patients without allergic
diseases (n/58) (c)
Control group
(n/31) (d)
(a)/(d), p/0.028
Median 45.5 172.0 35.0 24.0 (b)/(c), p/0.009
Range 2.0/4015.0 80.0/4015.0 2.0/502.0 3.0/151.0 (b)/(d), p/0.001
Mean9 /
SD
172.39 /494.1 509.09 /1053.4 91.09 /128.0 36.99 /38.9 (c)/(d), p /0.05
Table 3. Total IgE concentration in active and inactive SLE patients
IgE concentration (IU/ml) Statistical
significance
Active SLE patients
(n/24) (a)
Inactive SLE patients
(n/48) (b)
Control group
(n/31) (c)
Median 152.5 31.5 24.0 (a)/(b), p/0.003
Range 5.0/1166.0 2.0/4015.0 3.0/151.0 (a)/(c), p/0.0002
Mean9 /SD 209.69 /253.0 153.69 /579.9 36.99 /38.9 (b)/(c), p /0.05
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patients; especially, rhinitis (34%) and asthma (47%)
were present more often than in our examined
group.
The discrepancy of the obtained data may be
connected not only with immunological abnormal-
ities in lupus patients, but also with the geographical
differences. The outcomes of the European Commu-
nity Respiratory Health Survey indicate dissimilarities
in the frequency of allergic diseases in various
regions in the world, and pointed at the higher
incidence of allergic disorders in industrial coun-
tries.
12
The role of E immunoglobulins in immune com-
plex diseases has not been fully investigated. Some
authors claim that IgE, through the release of
vasoactive mediators from basophils and mast cells,
can cause increased vasopermeability, which may be
important in creating deposits of circulating com-
plexes in glomerulonephritis.
13 Others, however,
state that patients with SLE are not at increased risk
of IgE-mediated allergic disorders.
10
Although in our group of 72 patients the total IgE
concentration was significantly higher than in con-
trols, it seems that it was rather connected with
concomitant allergic diseases than with SLE by itself.
The lack of statistically significant differences be-
tween the IgE level in SLE patients without allergy
and the control group supports this statement.
Our previous investigations, performed only in SLE
patients during remission, revealed that the higher
IgE levels were connected with concomitant atopic
diseases and they were not related to SLE. In inactive
patients, without simultaneous atopic diseases, the
IgE level was not different from that in the general
population.
14
The aetiology of SLE is complex, and hereditary
factors play also an important role in the disease
pathogenesis. Sasai et al.
15 found the higher pre-
valence of allergic diseases in children of mothers
with SLE. In our group, the frequency of atopic
diseases (28%) in blood relatives of the patients was
higher than the frequency of these diseases in the
general population.
9
There are literature controversies concerning the
involvement of the reagin-type antibodies in auto-
immune diseases. Some authors postulate that IgE is
not related to the connective tissue diseases,
16 but
others suggest that they might play an essential
role.
17 Rebhun et al.
18 suggest that IgE antibodies
may mediate the release of chemical mediators and
facilitate local deposition of immune complexes, and
even though the IgE levels were between the normal
range the evidence is highly suggestive that the
increase of serum IgE accompanies disease activity
in most patients. The mean value of the IgE
concentration in SLE active patients was more than
three times higher than in inactive patients. The
authors investigated also a group of five patients
both in flares and in remission, and noticed the
elevation of the IgE level during exacerbation of the
disease. IgE antibody might be responsible for the
activation of mast cells in SLE patients for the release
of chemical mediators, especially histamine. The
knowledge of these associations is important from
the therapeutic point of view, as the antihistaminic
drugs may be helpful in the treatment of the disease
flares.
18
The relationship between serum IgE concentra-
tions and SLE activity has also been investigated. In
our group the highest total IgE levels were noted in
active SLE patients in whom those values were
significantly higher in comparison with inactive
patients as well as with the control group (p/0.003
and p/0.0002, respectively). There were no statis-
tical differences between the inactive group and
controls, which additionally supports the argument
that IgE plays a role in active stages of the disease.
Our results are in agreement with Elkayam et al.,
19
who found a statistically significant higher level of
this immunoglobulin in SLE patients during lupus
flares. Those authors stressed that the highest IgE
levels were detected in patients with lupus nephritis.
Only five patients in our group were observed during
flares ( /15 according to SLAM score) and remissions
(B/15 points). In all of them, significantly higher IgE
concentrations were noted during exacerbations of
the disease.
Some authors claim that in SLE patients the IgE
level cannot be regarded as a reliable feature of SLE
activation because multiple factors influence IgE
production.
20 In our opinion, this feature could serve
as a prognostic factor because in the whole SLE active
group the IgE concentration was significantly higher
than in inactive patients, and also in all five monitor-
ing patients during flares of the disease the IgE
concentration was significantly higher than in remis-
sion.
Environmental agents including drugs are known
as provoking and exacerbating factors in SLE pa-
tients.
21 The literature data concerning drug reactions
in lupus patient also give controversial results. Some
authors claim that drug reactions have a similar
frequency in SLE patients and healthy volunteers
group.
22 Others, however, postulate the increased
ratio in the SLE group.
5,23
In our study, drug reactions were very frequent in
SLE patients (36%). A population study performed 2
years ago on the group of 1900 inhabitants of our
region revealed drug reactions in 11.4%. This feature
was more common in women (14.7%) than in men
(8.8%).
24 Our observations are in line with Petri and
Allbritton.
23 Similarly to their report, penicillin/ce-
phalosporin were regarded as a main cause of drug
reactions in lupus patients. Contrary to their observa-
tions, in our patients flares of disease were rarely
A. Wozniacka et al.
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diagnose whether the lupus flare is connected with
infection or with drug, or is just spontaneous, without
any known reason.
The exact mechanism of increased prevalence of
drug reactions, especially antibiotic allergy, in lupus
patients is not completely understood. One possible
explanation of this fact is that SLE patients are more
exposed to antibiotics than the general population,
which may increase the chance of developing allergy
reactions.
There are not many reports regarding the preva-
lence of allergic contact dermatitis in SLE patients.
Goldman et al.
5 interviewed 24 patients for a history
of contact dermatitis defined as ‘erythema and/or
vesicles on exposure to simple chemicals’. No
differences between the SLE group (9/24, 37.5%)
and controls (12/27, 44.4%) were observed. They
concluded that the prevalence of contact dermatitis, a
cutaneous manifestation of cell-mediated immunity,
was similar in both groups. On the contrary, Sequeira
et al.
6 found that skin allergy was statistically
significant more frequent in SLE patients than in
controls (36% versus 17%; pB/0.01). However, in
their study, skin allergy was defined as ‘any urticarial
or erythematovesicular skin reactions directly related
to skin contact with allergens’, so contact urticaria as
well as irritant contact dermatitis were included in
their group. Morton et al.
10 interviewed 49 patients
with SLE, asking a question about skin reaction to
nickel or make-up resulting in redness and/or small
blisters, and found positive answers in 28.6% and
8.2% patients, respectively, compared with 41.8% and
10.2% controls. In our study, patch tests were
performed to prove allergy contact dermatitis. The
results are comparable with the expected frequency
of reactions to patch tests in different populations. In
the UK, Germany, the USA and Singapore, allergy to
nickel was found in 6.7/17.7% cases, to cobalt in
2.0/4.7% and to chromate in 0.9/6.8%.
25 So it seems
that the prevalence of allergic contact dermatitis in
SLE patients is not higher than in the general
population.
Despite many literature controversies and multiple
factors influencing IgE production, the obtained
results indicate that IgE may play a role in lupus
pathogenesis, especially in the active phase of the
disease, but further studies are still needed.
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